MedPath

Nicotine

Generic Name
Nicotine
Brand Names
Habitrol, Nicoderm C-Q, Nicorelief, Nicorette, Nicotrol
Drug Type
Small Molecule
Chemical Formula
C10H14N2
CAS Number
54-11-5
Unique Ingredient Identifier
6M3C89ZY6R
Background

Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke.

Indication

For the relief of nicotine withdrawal symptoms and as an aid to smoking cessation.

Associated Conditions
Withdrawal Nicotine
Associated Therapies
Smoking cessation therapy
Clinical Trials
Related News

Effects of E-Cigarette Flavors on Adults TCORS 2.0

Phase 1
Completed
Conditions
Nicotine Use Disorder
Interventions
Drug: Nicotine
Drug: Flavor
First Posted Date
2018-08-17
Last Posted Date
2024-02-15
Lead Sponsor
Yale University
Target Recruit Count
130
Registration Number
NCT03635333
Locations
🇺🇸

CMHC, Substance Abuse Center, New Haven, Connecticut, United States

Effects of Prazosin on the Attention-Enhancing Effects of Nicotine

Not Applicable
Withdrawn
Conditions
no Condition, Basic Science
Interventions
Drug: Placebo
Drug: Nicotine
Drug: Prazosin
Drug: Nicotine + Prazosin
First Posted Date
2018-01-31
Last Posted Date
2019-08-19
Lead Sponsor
University of Maryland, Baltimore
Registration Number
NCT03416569

Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites

Phase 4
Active, not recruiting
Conditions
Smoking Cessation
Interventions
Drug: Nicotine Lozenge
Drug: Nicotine Replacement Therapy (NRT)
Behavioral: Motivational Interviewing (MI)
Behavioral: Message Framing
Other: saliva sample
First Posted Date
2017-10-20
Last Posted Date
2025-01-06
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
807
Registration Number
NCT03315910
Locations
🇺🇸

University of Southern California, Los Angeles, California, United States

🇺🇸

WellStar Health System, LaGrange, Georgia, United States

🇺🇸

Maine Medical Center Cancer Institute, Scarborough, Maine, United States

and more 15 locations

The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine

Phase 1
Withdrawn
Conditions
Cognitive Change
Interventions
Drug: Placebo
Drug: Nicotine
Drug: AVL-3288
Drug: Nicotine + AVL-3288
First Posted Date
2017-09-13
Last Posted Date
2024-11-06
Lead Sponsor
University of Maryland, Baltimore
Registration Number
NCT03281694

Efficacy and Safety of E-cigarettes for Smoking Cessation in Middle-aged Heavy Smokers

Phase 4
Completed
Conditions
Smoking Cessation
Electronic Cigarette
Interventions
Drug: Varenicline Tartrate
Drug: Nicotine
Behavioral: Motivational Interview
First Posted Date
2017-08-01
Last Posted Date
2024-05-16
Lead Sponsor
University of Oulu
Target Recruit Count
450
Registration Number
NCT03235505
Locations
🇫🇮

Lapland Central Hospital, Rovaniemi, Finland

Flavors and E-cigarette Effects in Adolescent Smokers- STUDY 2

Phase 1
Completed
Conditions
Nicotine Dependence
Interventions
Drug: Nicotine
Other: Menthol Flavor
Other: Experimental Flavor
First Posted Date
2017-05-30
Last Posted Date
2020-05-04
Lead Sponsor
Yale University
Target Recruit Count
56
Registration Number
NCT03168191
Locations
🇺🇸

CMHC, Substance Abuse Center, New Haven, Connecticut, United States

Effects of Exercise and Nicotine on Cognition in Smokers

Phase 3
Completed
Conditions
Smoking Cessation
Interventions
Drug: Nicotine
Behavioral: Moderate Intensity Exercise
First Posted Date
2017-03-27
Last Posted Date
2024-05-03
Lead Sponsor
Western University, Canada
Target Recruit Count
34
Registration Number
NCT03091699
Locations
🇨🇦

Western University, London, Ontario, Canada

Vaping THC From Electronic Cigarettes

Phase 3
Completed
Conditions
Marijuana Dependence
Interventions
Drug: Nicotine
Drug: Cannabis
Device: PAX Loose Leaf Vaporizer
First Posted Date
2016-11-04
Last Posted Date
2023-06-29
Lead Sponsor
University of California, San Francisco
Target Recruit Count
8
Registration Number
NCT02955329
Locations
🇺🇸

Zuckerberg San Francisco General Hospital, San Francisco, California, United States

Nicotine Replacement Therapy in Nicotine-dependent Arrestees

Phase 4
Completed
Conditions
Nicotine Dependence
Interventions
Drug: Nicotine patch
Other: placebo patch
First Posted Date
2016-09-19
Last Posted Date
2021-06-28
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
800
Registration Number
NCT02905734
Locations
🇫🇷

Médecine légale - Hôpital Jean Verdier, Bondy, France

Smoking Treatment and Exercise Program for Underserved Populations (STEP UP)

Not Applicable
Completed
Conditions
Smoking
Interventions
Behavioral: Cognitive Behavioral Counseling
Behavioral: Mobile Contingency Management
Drug: Bupropion
Drug: Transdermal nicotine patch
Drug: Nicotine polacrilex
Drug: Nicotine lozenge
First Posted Date
2016-08-19
Last Posted Date
2018-07-13
Lead Sponsor
Duke University
Target Recruit Count
11
Registration Number
NCT02873754
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy